Regeneron EVP Marion McCourt sells 1,132 shares

After the sale, Marion McCourt reported 10,871 shares held directly and 219 shares through the 401(k) Plan.

Available on EDGAR 11/03/2026 - 04:03 PM EST Accepted by SEC EDGAR 11/03/2026 - 04:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, Inc. (REGN), sold 1,132 shares of common stock on October 30, 2026, at $869.43 per share. The sale was made under a plan intended to comply with Rule 10b5-1(c), adopted on February 17, 2026. After the sale, McCourt reported 10,871 shares held directly; the report also lists 219 shares held indirectly through the 401(k) Plan.

Insider Trade Summary 10b5-1

Net Seller: 1,132 shares

Net Sell 1 txn

Insider McCourt Marion

Role EVP Commercial

Sold 1,132 shs ($984K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,132	$869.43	$984K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 10,871 shares (Direct); Common Stock — 219 shares (Indirect, By 401(k) Plan)

Footnotes (1)

1. F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.

Key Figures

Shares sold: 1,132 shares Sale price per share: $869.43 per share Direct shares after sale: 10,871 shares +1 more

4 metrics

Shares sold 1,132 shares October 30, 2026

Sale price per share $869.43 per share October 30, 2026 sale

Direct shares after sale 10,871 shares Reported after the October 30, 2026 sale

Shares held through 401(k) Plan 219 shares Reported after the October 30, 2026 transaction

Key Terms

Rule 10b5-1(c), 401(k) Plan, Direct ownership

3 terms

Rule 10b5-1(c) regulatory

"plan intended to comply with Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

401(k) Plan financial

"By 401(k) Plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

Direct ownership financial

"10,871 shares held directly after the sale"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did Marion McCourt sell, and at what price?

Marion McCourt sold 1,132 shares at $869.43 per share on October 30, 2026.

Was Marion McCourt's REGN sale under a Rule 10b5-1 plan?

Yes. The sale was made under a plan intended to comply with Rule 10b5-1(c), adopted on February 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCourt Marion

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NEW YORK 10591

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Commercial

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2026		S(1)		1,132	D	$869.43	10,871	D
Common Stock								219	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.

	/s/ Marion McCourt	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)